文献速递临床试验与 GCP基础与转化研究

口服褪黑素作为早产儿神经保护新工具:随机对照试验研究方案

Oral melatonin as a new tool for neuroprotection in preterm newborns: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2021-01-22

该研究为前瞻性、多中心、双盲、随机对照试验,计划在出生96小时内招募60名胎龄≤29周+6天的早产儿,随机接受口服褪黑素3 mg/kg/天或安慰剂15天。主要结局为血浆丙二醛水平,并将在矫正年龄24个月内评估神经发育结局。

要点

  • 口服褪黑素3 mg/kg/天用于胎龄≤29周+6天早产儿,连续15天。
  • 主要结局为血浆丙二醛水平,作为褪黑素治疗效果的早期生物标志物。
  • 将在矫正年龄24个月内监测神经发育结局。

核心结论

  • 该研究旨在评估褪黑素减轻早产所致脑损伤的能力,为早产儿神经保护提供依据。

研究设计与样本

  • 前瞻性、多中心、双盲、随机对照试验,计划招募60名胎龄≤29周+6天的早产儿,出生96小时内随机分组。

关键数值与推荐

  • 干预为口服褪黑素3 mg/kg/天或安慰剂,持续15天。
  • 主要结局为血浆丙二醛水平。
  • 次要结局包括矫正年龄24个月内的神经发育评估、支气管肺发育不良和脓毒症发生率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prevention of neurodevelopmental impairment due to preterm birth is a major health challenge. Despite advanced obstetric and neonatal care, to date there are few neuroprotective molecules available. Melatonin has been shown to have anti-oxidant/anti-inflammatory effects and to reduce brain damage, mainly after hypoxic ischemic encephalopathy. The planned study will be the first aiming to evaluate the capacity of melatonin to mitigate brain impairment due to premature birth. METHOD: In our planned prospective, multicenter, double-blind, randomized vs placebo study, we will recruit, within 96 h of birth, 60 preterm newborns with a gestational age ≤ 29 weeks + 6 days; these infants will be randomly allocated to oral melatonin, 3 mg/kg/day, or placebo for 15 days. After the administration period, we will measure plasma levels of malondialdehyde, a lipid peroxidation product considered an early biological marker of melatonin treatment efficacy (primary outcome). At term-equivalent age, we will evaluate neurological status (through cerebral ultrasound, cerebral magnetic resonance imaging, vision and hearing evaluations, clinical neurological assessment, and screening for retinopathy of prematurity) as well as the incidence of bronchodysplasia and sepsis. We will also monitor neurodevelopmental outcome during the first 24 months of corrected age (using the modified Fagan Test of Infant Intelligence at 4-6 months and standardized neurological and developmental assessments at 24 months). DISCUSSION: Preterm birth survivors often present long-term neurodevelopmental sequelae, such as motor, learning, social-behavioral, and communication problems. We aim to assess the role of melatonin as a neuroprotectant during the first weeks of extrauterine life, when preterm infants are unable to produce it spontaneously. This approach is based on the supposition that its anti-oxidant mechanism could be useful in preventing neurodevelopmental impairment. Considering the short- and long-term morbidities related to preterm birth, and the financial and social costs of the care of preterm infants, both at birth and over time, we suggest that melatonin administration could lead to considerable saving of resources. This would be the first study addressing the role of melatonin in very low birth weight preterm newborns, and it could provide a basis for further studies on melatonin as a neuroprotection strategy in this vulnerable population. TRIAL REGISTRATION: ClinicalTrials.gov NCT04235673 . Prospectively registered on 22 January 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Garofoli F, Longo S, Pisoni C, et al. Oral melatonin as a new tool for neuroprotection in preterm newborns: study protocol for a randomized controlled trial. Trials. 2021. PMID: 33482894. doi:10.1186/s13063-021-05034-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。